Provided by Tiger Trade Technology Pte. Ltd.

Theriva Biologics

0.2200
+0.020110.06%
Post-market: 0.2056-0.0144-6.55%19:58 EST
Volume:2.37M
Turnover:478.76K
Market Cap:7.85M
PE:-0.04
High:0.2200
Open:0.2000
Low:0.1912
Close:0.1999
52wk High:1.75
52wk Low:0.1651
Shares:35.69M
Float Shares:34.94M
Volume Ratio:1.01
T/O Rate:6.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5306
EPS(LYR):-19.0286
ROE:-166.96%
ROA:-29.21%
PB:1.17
PE(LYR):-0.01

Loading ...

Theriva Biologics stellt Phase-1-Studienergebnisse zu VCN-01 bei refraktärem Retinoblastom vor

Reuters
·
Feb 03

Theriva™ Biologics Announces Upcoming Presentation of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial at Apao 2026

THOMSON REUTERS
·
Feb 03

Why Is Theriva Biologics Stock Gaining Monday?

Benzinga_recent_news
·
Dec 30, 2025

Theriva Biologics Inc - Cash Runway Until Q1 2027 Supports Vcn-01 Trials

THOMSON REUTERS
·
Dec 29, 2025

Theriva™ Biologics Announces Positive Scientific Advice From the European Medicines Agency (Ema) on the Design of a Phase 3 Trial of Vcn-01 in Metastatic Pancreatic Ductal Adenocarcinoma (Pdac)

THOMSON REUTERS
·
Dec 29, 2025

Theriva Biologics Inc - to Schedule End-of-Phase 2 Meeting With FDA in H1 2026

THOMSON REUTERS
·
Dec 29, 2025

Theriva Biologics Seeks Shareholder Approval for Issuance of 16.2 Million Shares Under Warrant Agreement

Reuters
·
Dec 16, 2025

Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year

TIPRANKS
·
Nov 12, 2025

Theriva Biologics Q3 EPS $(0.45) Beats $(1.13) Estimate

Benzinga
·
Nov 12, 2025

Theriva Biologics reports third quarter loss and lower R&D expenses

Reuters
·
Nov 12, 2025

Theriva Biologics Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Nov 01, 2025

Theriva Biologics: No Material Development to Account for Stock Activity

Dow Jones
·
Oct 25, 2025

Theriva Biologics sees no material development to account for unusual trading

TIPRANKS
·
Oct 25, 2025

Theriva Biologics Provides Response to Unusual Market Action

GlobeNewswire
·
Oct 25, 2025

Theriva Biologics Presents Promising Phase 2b Trial Data

TIPRANKS
·
Oct 21, 2025

Theriva Biologics Secures $4M Through Warrant Agreement

TIPRANKS
·
Oct 18, 2025

Theriva Biologics Raises $4 Million Through Warrant Inducement Private Placement

Reuters
·
Oct 18, 2025

Theriva Biologics announces warrant inducement transaction for $4M in proceeds

TIPRANKS
·
Oct 16, 2025

Theriva Biologics Announces New Preclinical Data and Next-Generation Oncolytic Adenovirus VCN-12 at ESGCT Congress, Highlighting Advances in Cancer Treatment

Reuters
·
Oct 06, 2025

Theriva Biologics Restructures, Cuts Workforce by 32%

TIPRANKS
·
Oct 03, 2025